Randomized Neoadjuvant Study of Epirubicin and Docetaxel With/Without Capecitabine in Early Breast Cancer

Breast Cancer Clinical Trial

Official title:

A Randomized Phase III Study Comparing Epirubicin, Docetaxel and Capecitabine + G-CSF to Epirubicin and Docetaxel + G-CSF as Neoadjuvant Treatment for Early HER-2 Negative Breast Cancer and Comparing Epirubicin, Docetaxel and Capecitabine + G-CSF ± Trastuzumab to Epirubicin and Docetaxel + G-CSF ± Trastuzumab as Neoadjuvant Treatment for Early HER-2 Positive Breast Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00309556
• Other study ID #: ABCSG-24
• Secondary ID: Ro 09-1978
• Status: Completed
• Phase: Phase 3
• First received: March 31, 2006
• Last updated: December 29, 2011
• Start date: February 2005
• Est. completion date: November 2011

Study information

• Verified date: December 2011
• Source: Austrian Breast & Colorectal Cancer Study Group
• Contact: n/a
• Is FDA regulated: No
• Health authority: Austria: Federal Office for Safety in Health Care
• Study type: Interventional

Clinical Trial Summary

Primarily, this clinical investigation compares the rates (percentages) of pathological complete remissions attained at the time of final surgery following 6 cycles each of epirubicin + docetaxel + capecitabine-containing chemotherapy ± trastuzumab (in HER-2 positive disease) vs. epirubicin + docetaxel-containing chemotherapy ± trastuzumab (in HER-2 negative disease).

Description:

This study is a prospective, randomized, multicentre, phase III trial in the neoadjuvant treatment of patients with primary breast cancer and no distant metastases. Patients will be stratified at inclusion according to the centre, to the clinical tumour stage (T1, T2, T3, T4a-c), the axillary lymph node status (positive, negative), the menopausal status (pre-menopausal, post-menopausal), histology (invasive ductal, invasive lobular, mixed), the hormone-receptor status (positive [ER+/PR+, ER+/PR-, ER-/PR+], negative [ER-/PR-], not determinable]), the HER-2 status (positive, negative, not determinable), the grading (G1/G2, G3, not determinable) and will be randomly assigned to receive either 6 cycles of neoadjuvant epirubicin, docetaxel and capecitabine ± trastuzumab in HER-2 positive disease or 6 cycles of neoadjuvant epirubicin and docetaxel ± trastuzumab in HER-2 positive disease.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 536
• Est. completion date: November 2011
• Est. primary completion date: November 2009
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 19 Years to 80 Years

Eligibility

Inclusion Criteria:

• Female patients with histologically proven, core-biopsied, invasive breast cancer of any clinical and/or radiological T-stage (except for T4d)

• Age 18-70 years

• WHO performance status = 2

• No prior or current neoplasm except for curatively treated non-melanoma skin cancer, in situ carcinoma of the cervix

• No distant disease / secondary carcinoma judged clinically and at least by chest X-ray, liver sonography, and bone scan upon randomization

• No medical and/or cardiologic contraindication to receive an anthracycline- and taxane-containing chemotherapy regimen. Normal cardiac function must be confirmed by LVEF (echocardiography or Muga scan). The result must be above 50% or above the institution's ULN

• Results of the following assessments at the time of randomization must be available:

1. chest wall CT, abdomen CT, bilateral mammography: within 4 weeks before enrolment;

2. laboratory requirements: within 2 weeks before enrolment

3. hematology: neutrophils = 4.0 x 109/l, platelets = 150 x 109/l, haemoglobin = 13 g/dl

4. hepatic function: total bilirubin < 1 x ULN, ASAT (SGOT) and ALAT (SGPT) < 1x ULN, alkaline phosphatase < 1 x ULN. In case of abnormal values, liver function tests have to be repeated within 3 days before study treatment.

5. renal function: creatinine = 1 x ULN,

6. histology, grading, hormone receptor status, HER-2/neu status

• Signed and dated informed consent before the start of specific protocol procedures

• Negative pregnancy test in the presence of childbearing potential

Exclusion Criteria:

• Stage T4d / inflammatory breast cancer

• Pregnant or lactating patients; patients of childbearing potential must implement adequate contraceptive measures during study participation

• Pre-existing motor or sensory neurotoxicity of a severity = WHO grade 2

• Preoperative local treatment for breast cancer (i.e. incomplete surgery, radiotherapy)

• Prior or concomitant systemic antitumor therapy

• Other serious illness or medical condition

1. congestive heart failure or unstable angina pectoris, even if medically controlled.

Previous history of myocardial infarction within 1 year from study entry, uncontrolled hypertension or high-risk uncontrolled arrythmias

2. history of significant neurologic or psychiatric disorders, including psychotic disorders, dementia or seizures that would prohibit the understanding and giving of informed consent

3. active uncontrolled infection

4. unstable peptic ulcer, unstable diabetes mellitus or other contraindication for the use of corticosteroids

• Concurrent treatment with corticosteroids except as use for the prophylactic regimen, inhalational use, treatment of acute hypersensitivity reactions, treatment of nausea/vomiting or chronic treatment (initiated > 6 months prior to study entry) at low dose (= 20 mg methylprednisolone or equivalent)

• Known hypersensitivity against taxanes and/or epirubicin and/or fluorouracil/capecitabine

• Known dihydropyrimidine-dehydrogenase (DPD) deficit

• Treatment with an investigational drug within 30 days prior to study entry

• Legally incapacitated and/or other circumstances which make it unfeasible for the subject to understand the nature, meaning and consequences of the clinical study

• Concurrent psychiatric illness according to ICD (alcohol addiction) at the time of study entry

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• Epirubicin
6 cycles 75mg/m2 i.v. day 1 q3w
• Docetaxel
6 cycles 75mg/m2 i.v. day 1 q3w
• Capecitabine
6 cycles 1000mg/m2 oral, day 1-14 q2d
• Trastuzumab
cycle 1: 8mg/kg i.v. day 1 cycle 2-6: 6mg/kg i.v. day 1 (=6 cycles q3w)

Locations

Country	Name	City	State
Austria	Hospital Baden	Baden bei Wien	Lower Austria
Austria	Gynaegological Medical University Graz	Graz	Styria
Austria	Medical University of Graz, Oncology	Graz	Styria
Austria	Hospital Guessing	Guessing	Burgenland
Austria	Medical University of Innsbruck	Innsbruck	Tyrol
Austria	State Hospital Kirchdorf	Kirchdorf	Upper Austria
Austria	State Hospital Klagenfurt	Klagenfurt	Carinthia
Austria	Hospital Krems	Krems	Lower Austria
Austria	District Hospital Kufstein	Kufstein	Tyrol
Austria	State Hospital Leoben	Leoben	Styria
Austria	General Hospital Linz	Linz	Upper Austria
Austria	Hospital BHS Linz	Linz	Upper Austria
Austria	Hospital Oberpullendorf	Oberpullendorf	Burgenland
Austria	Hospital Oberwart	Oberwart	Burgenland
Austria	State Hospital Feldkirch/Rankweil	Rankweil	Vorarlberg
Austria	Paracelsus Medical University Salzburg - Oncology	Salzburg
Austria	Hospital BHB St. Veit/Glan, Surgery	St. Veit a. d. Glan	Carinthia
Austria	Ordination Dr. Wette	St. Veit a. d. Glan	Carinthia
Austria	State Hospital Steyr	Steyr	Upper Austria
Austria	Hanusch Hospital	Vienna
Austria	Medical University Vienna, General Hospital	Vienna
Austria	State Hospital Vienna-Hietzing	Vienna
Austria	State Hospital Villach	Villach	Carinthia
Austria	Klinikum Wels-Grieskirchen	Wels	Upper Austria
Austria	Hospital of Wiener Neustadt	Wiener Neustadt	Lower Austria
Austria	State Hospital Wolfsberg	Wolfsberg	Carinthia

Sponsors (5)

Lead Sponsor	Collaborator
Austrian Breast & Colorectal Cancer Study Group	Amgen, Ebewe Pharma GmbH, Hoffmann-La Roche, Sanofi

Country where clinical trial is conducted

Austria, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of pathological complete remissions	at the time of final surgery after 6 cycles of Arm A (Epirubicin/ Docetaxel/ Capecitabine-containing chemotherapy ± Trastuzumab in HER-2 positive disease) vs. Arm B (Epirubicin/Docetaxel-containing chemotherapy ± Trastuzumab in HER-2 positive disease).	20 weeks	No
Secondary	Rates of axillary lymph node involvement and breast-conserving procedures	at the time of final surgery in Arm A (± trastuzumab in HER-2 positive disease) vs. Arm B (± trastuzumab in HER-2 positive disease).	20 weeks	No

External Links

•   Click here for more information about this study: ABCSG-Studien closed